LLY

1,032.05

+2.06%↑

JNJ

247.48

+1.82%↑

ABBV

229.64

+2.7%↑

NVS

169.14

+2.26%↑

MRK

122.85

+2.8%↑

LLY

1,032.05

+2.06%↑

JNJ

247.48

+1.82%↑

ABBV

229.64

+2.7%↑

NVS

169.14

+2.26%↑

MRK

122.85

+2.8%↑

LLY

1,032.05

+2.06%↑

JNJ

247.48

+1.82%↑

ABBV

229.64

+2.7%↑

NVS

169.14

+2.26%↑

MRK

122.85

+2.8%↑

LLY

1,032.05

+2.06%↑

JNJ

247.48

+1.82%↑

ABBV

229.64

+2.7%↑

NVS

169.14

+2.26%↑

MRK

122.85

+2.8%↑

LLY

1,032.05

+2.06%↑

JNJ

247.48

+1.82%↑

ABBV

229.64

+2.7%↑

NVS

169.14

+2.26%↑

MRK

122.85

+2.8%↑

Search

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

29.83 -0.86

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

29.8

Max

30.7

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-10M

-67M

Pelno marža

-7,753.425

Darbuotojai

186

EBITDA

-9.8M

-73M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+65.93% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-03-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

111M

1.6B

Ankstesnė atidarymo kaina

30.69

Ankstesnė uždarymo kaina

29.83

Naujienos nuotaikos

By Acuity

50%

50%

168 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-26 22:04; UTC

Uždarbis

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

2026-02-26 23:55; UTC

Rinkos pokalbiai

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

2026-02-26 23:40; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

2026-02-26 23:37; UTC

Rinkos pokalbiai

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

2026-02-26 23:32; UTC

Uždarbis

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

2026-02-26 23:19; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

2026-02-26 23:18; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

2026-02-26 23:12; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2026-02-26 23:12; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Netflix Gives Up in Bidding War Over Warner -- Market Talk

2026-02-26 23:01; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

2026-02-26 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

2026-02-26 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

2026-02-26 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

2026-02-26 22:43; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-26 22:43; UTC

Rinkos pokalbiai

RBA Hike In March Is Being Underpriced -- Market Talk

2026-02-26 22:33; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

2026-02-26 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

2026-02-26 22:13; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Bidding War Over Warner Bros. Set to Continue -- Market Talk

2026-02-26 21:59; UTC

Uždarbis

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

2026-02-26 21:58; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

2026-02-26 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-26 21:49; UTC

Uždarbis

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

2026-02-26 21:45; UTC

Uždarbis

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

2026-02-26 21:44; UTC

Uždarbis

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

2026-02-26 21:44; UTC

Uždarbis

Coles Expects Market to Remain Highly Competitive

2026-02-26 21:44; UTC

Uždarbis

Coles Says Supermarket Customers Remain Value Oriented

2026-02-26 21:43; UTC

Uždarbis

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

2026-02-26 21:43; UTC

Uždarbis

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

2026-02-26 21:42; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

2026-02-26 21:41; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

65.93% į viršų

12 mėnesių prognozė

Vidutinis 51.14 USD  65.93%

Aukščiausias 70 USD

Žemiausias 24 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

7

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

168 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat